logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—Adjuvant VEGF-TKIs have no benefit, are toxic for high-risk renal cell carcinoma

NCCN and EAU recommend oral TKIs as first-line treatments for RCC.